V
2.13
0.16 (7.87%)
| Previous Close | 1.97 |
| Open | 2.03 |
| Volume | 101,645 |
| Avg. Volume (3M) | 832,339 |
| Market Cap | 3,825,000 |
| Price / Sales | 20.23 |
| Price / Book | 7.65 |
| 52 Weeks Range | |
| Earnings Date | 29 May 2025 - 2 Jun 2025 |
| Operating Margin (TTM) | -14,450.00% |
| Diluted EPS (TTM) | -10.08 |
| Quarterly Revenue Growth (YOY) | 380.00% |
| Total Debt/Equity (MRQ) | 291.21% |
| Current Ratio (MRQ) | 0.710 |
| Operating Cash Flow (TTM) | -10.10 M |
| Levered Free Cash Flow (TTM) | -5.72 M |
| Return on Assets (TTM) | -123.36% |
| Return on Equity (TTM) | -378.40% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | VivoSim Labs, Inc. | - | - |
AIStockmoo Score
-1.1
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -4.0 |
| Average | -1.13 |
|
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.53% |
| % Held by Institutions | 12.21% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 23 Apr 2025 | Announcement | VivoSim to Carry Forward Organovo 3D Bioprinting |
| 02 Apr 2025 | Announcement | Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements |
| 27 Mar 2025 | Announcement | Organovo Provides Business Update |
| 25 Mar 2025 | Announcement | Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company |
| 19 Mar 2025 | Announcement | Organovo Announces Reverse Stock Split |
| 06 Mar 2025 | Announcement | Organovo Announces the Issuance of Additional Shares in Conjunction with Warrant Exercises |
| 25 Feb 2025 | Announcement | Organovo’s FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |